Research programme: epigenetic cancer therapies - Aptose Biosciences/Moffitt Cancer Center

Drug Profile

Research programme: epigenetic cancer therapies - Aptose Biosciences/Moffitt Cancer Center

Alternative Names: APL-581; BET inhibitors - Aptose Biosciences; Bromodomain inhibitors - Aptose Biosciences; MA2 014; MA2-1014

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Myeloproliferative disorders; Solid tumours

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical studies in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 03 Dec 2015 Pharmacodynamics data from a preclinical trial in Myeloproliferative disorders released by Aptose Biosciences
  • 01 Dec 2015 Preclinical trials in Myeloproliferative disorders in USA (unspecified route) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top